Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · November 21, 2023

Clinical Benefit of Cemiplimab in Patients With Locally Advanced Basal Cell Carcinoma After Hedgehog Inhibitor Therapy

Journal of the American Academy of Dermatology


Additional Info

Journal of the American Academy of Dermatology
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up
J Am Acad Dermatol 2023 Oct 13;[EPub Ahead of Print], AJ Stratigos, A Sekulic, K Peris, O Bechter, S Prey, KD Lewis, N Basset-Seguin, ALS Chang, S Dalle, A Fernandez Orland, L Licitra, C Robert, C Ulrich, A Hauschild, MR Migden, R Dummer, SY Yoo, E Okoye, I Bassukas, C Loquai, V De Giorgi, Z Eroglu, R Gutzmer, J Ulrich, S Puig, TJ Inocencio, CI Chen, PR LaFontaine, F Seebach, I Lowy, MG Fury

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading